Research Article

GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer

*Author for correspondence:

E-mail Address: 1744061913@qq.com

Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, PR China

^‡Authors contributed equally

Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, PR China

^‡Authors contributed equally

Search for more papers by this author

Williams Walana^‡

Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, PR China

Department of Clinical Microbiology, University for Development Studies, Tamale, Ghana

^‡Authors contributed equally

Search for more papers by this author

Feng Zhao

College of Basic Medical Science, Dalian Medical University, #9 West Section Lvshun South Road, Dalian, 116044, Liaoning, PR China

Search for more papers by this author

Fang Li

**Author for correspondence:

E-mail Address: lifang@dmu.edu.cn

Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, PR China

Search for more papers by this author

Fuwen Luo

^***Author for correspondence:

E-mail Address: fuwenluo@aliyun.com

Department of Acute Abdominal Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116044, Liaoning, PR China

Search for more papers by this author

Published Online:14 Apr 2020https://doi.org/10.2217/fon-2020-0035

View article

Abstract

Aim: Herein is presented the combined effect of PI3K inhibitor (GDC-0941) and CXCR1/2 analogue (G31P) in breast cancer. Materials & methods: Breast cancer cell lines and xenograft model were employed to test the efficacy of the combination therapy. Results: GDC-0941+G31P treatment substantially inhibited multiplication of all the breast cancer cell lines used in this study (BT474, HCC1954 and 4T1). Even though single therapies caused a meaningful S-phase cell cycle arrest, the inhibition effect was more potent with the combined treatment. Similarly, enhanced apoptosis accompanied GDC-0941+G31P treatment. Furthermore, the migration ability of the breast cancer cell lines were significantly curtailed by the combination therapy compared with the single treatments. Conclusion: The findings suggest that combination treatment involving PI3K inhibitor and CXCR1/2 analogue (G31P) could be a potent therapeutic option for breast cancer treatment.

Keywords:

Papers of special note have been highlighted as: • of interest

Reference

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 490(7418), 61–70 (2012).
MedlineGoogle Scholar
2. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554–554 (2004).
Medline CASGoogle Scholar
3. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13(2), 140–156 (2014).
Medline CASGoogle Scholar
4. Lau MT, Leung PCK. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 326(2), 191–198 (2012). • The role of PI3K/Akt/mTOR signaling in cancer.
Medline CASGoogle Scholar
5. O'Donnell JS, Massi D, Teng MW et al. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin. Cancer Biol. 48, 91–103 (2018).
MedlineGoogle Scholar
6. Mabuchi S, Kuroda H, Takahashi R et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol. Oncol. 137(1), 173–179 (2015). • The PI3K/AKT/mTOR pathway plays a crucial role in ovarian cancer.
Medline CASGoogle Scholar
7. Lachkar B, Minaguchi T, Akiyama A et al. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Medicine 97, 31 (2018).
Google Scholar
8. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation and colorectal-cancer survival. N. Engl. J. Med. 367(17), 1596–1606 (2012).
Medline CASGoogle Scholar
9. Kim ST, Lee J, Park SH et al. Prospective Phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer 17(1), 211 (2017).
MedlineGoogle Scholar
10. Sarker D, Ang JE, Baird R et al. First-in-human Phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 21(1), 77–86 (2015).
Medline CASGoogle Scholar
11. Leong S, Moss RA, Bowles DW et al. A Phase I dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with erlotinib in patients with advanced solid tumors. Oncologist 22(12), 1491–1499 (2017).
Medline CASGoogle Scholar
12. Yamamoto N, Fujiwara Y, Tamura K et al. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with nonsquamous non-small-cell lung cancer. Invest. New Drugs 35(1), 37–46 (2017).
Medline CASGoogle Scholar
13. Le X, Antony R, Razavi P et al. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discov. 6(10), 1134–1147 (2016).
Medline CASGoogle Scholar
14. Raynaud FI, Eccles SA, Patel S et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 8(7), 1725–1738 (2009).
Medline CASGoogle Scholar
15. Vora SR, Juric D, Kim N et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26(1), 136–149 (2014).
Medline CASGoogle Scholar
16. Ilic N, Utermark T, Widlund HR et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotictranslation initiation factor 4E (elF4E) axis. Proc. Natl Acad. Sci. 108(37), 699–708 (2011).
Medline CASGoogle Scholar
17. Bosch A, Li Z, Bergamaschi A et al. PI3K inhibition results in enhanced estrogen receptor. 7(283), 283ra51–283ra51 (2015).
Google Scholar
18. Juric D, Castel P, Griffith M et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature 518(7538), 240–244 (2015).
Medline CASGoogle Scholar
19. Costa C, Ebi H, Martini M et al. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 27(1), 97–108 (2015).
Medline CASGoogle Scholar
20. Elkabets M, Vora S, Juric D et al. mTORCI inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5(196), 196ra99–196ra99 (2013).
MedlineGoogle Scholar
21. Junttila TT, Akita RW, Parsons K et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15(5), 429–440 (2009). • Combination treatment involving GDC-0941 and trastuzumab.
Medline CASGoogle Scholar
22. Hoeflich KP, O'Brien C, Boyd Z et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 15(14), 4649–4664 (2009).
Medline CASGoogle Scholar
23. Yao E, Zhou W, Lee-Hoeflich ST et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab and pertuzumab. Clin. Cancer Res. 15(12), 4147–4156 (2009).
Medline CASGoogle Scholar
24. Khan MN, Wang B, Wei J et al. CXCR1/2 antagonism with CXCL8/interleukin-8 analogue CXCL8 (3–72) K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis. Oncotarget 6(25), 21315–21327 • Antiproliferative and anti-angiogenic effect of CXCL8 analogue, G31P.
MedlineGoogle Scholar
25. Wei J, Chen X, Li Q et al. ELR-CXC chemokine antagonism and cisplatin cotreatment additively reduce H22 hepatoma tumor progression and ame liorate cisplatin-induced nephrotoxicity. Oncol. Rep. 31(4), 1599–1604 (2014).
Medline CASGoogle Scholar
26. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15(1), 7–24 (2015).
Medline CASGoogle Scholar
27. Rodon J, Dienstmann R, Serra V et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10(3), 143–153 (2013).
Medline CASGoogle Scholar
28. Zhang QW, Liu L, Gong CY et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7(12), e50946 (2012).
Medline CASGoogle Scholar
29. Martin M, Wei H, Lu T. Targeting microenvironment in cancer therapeutics. Oncotarget 7(32), 52575–52583 (2016).
MedlineGoogle Scholar
30. Usman MW, Gao J, Zheng T et al. Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling. Cell Death Dis. 9(8), 809 (2019). • The role of macrophages in promoting cancer.
Google Scholar
31. Walana W, Ye Y, Li M et al. IL-8 antagonist, CXCL8(3-72)K11R/G31P coupled with probiotic exhibit variably enhanced therapeutic potential in ameliorating ulcerative colitis. Biomed. Pharmacother. 103, 253–261 (2018).
Medline CASGoogle Scholar
32. Walana W, Wang JJ, Yabasin IB et al. IL-8 analogue CXCL8 (3-72) K11R/G31P, modulates LPS-induced inflammation via AKT1-NF-kβ and ERK1/2-AP-1 pathways in THP-1 monocytes. Hum. Immunol. 79(11), 809–816 (2018). • The role of CXCL8 antagonist in regulating inflammation.
Medline CASGoogle Scholar
33. Wang Y, Wu L, Tian C et al. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann. Hematol. 97(2), 229–237 (2018).
Medline CASGoogle Scholar
34. Byun DJ, Wolchok JD, Rosenberg LM et al. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13(4), 195–207 (2017).
Medline CASGoogle Scholar
35. Cui S, Zhu Y, Du J et al. CXCL8 antagonist improves diabetic nephropathy in male mice with diabetes and attenuates high glucose–induced mesangial injury. Endocrinology 158(6), 1671–184 (2017).
Medline CASGoogle Scholar
36. Acharyya S, Oskarsson T, Vanharanta S et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1), 165–178 (2012).
Medline CASGoogle Scholar
37. Caunt M, Hu L, Tang T et al. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res. 66(8), 4125–4132 (2006).
Medline CASGoogle Scholar
38. Tang Z, Yu M, Miller F et al. Increased invasion through basement membrane by CXCL7-transfected breast cells. Am. J. Surg. 196(5), 690–696 (2006).
Google Scholar
39. Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol. Cancer Res. 10(10), 1294–1305 (2012).
Medline CASGoogle Scholar
40. Ryan D, Bogan D, Davies J et al. A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment. Oncotarget 8(61), 103182–103206 (2017).
MedlineGoogle Scholar
41. Sharma B, Nawandar DM, Nannuru KC et al. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis and lung metastasis. Mol. Cancer Ther. 12(5), 799–808 (2013).
Medline CASGoogle Scholar
42. Nannuru KC, Sharma B, Varney ML et al. Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J. Carcinog. 10(40), (2011). • CXCR2 over-expression in cancer as a target for inhibiting tumor angiogenesis and metastasis.
MedlineGoogle Scholar
43. Ginestier C, Liu S, Diebel ME et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120(2), 485–497 (2010).
Medline CASGoogle Scholar
44. Brandolini L, Cristiano L, Fidoamore A et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget 6(41), 43375–43394 (2015).
MedlineGoogle Scholar
45. Shi L, Gao X, Li X et al. Ellagic acid enhances the efficacy of PI3K inhibitor GDC-0941 in breast cancer cells. Curr. Mol. Med. 15(5), 478–486 (2015).
Medline CASGoogle Scholar
46. Li L, Khan MN, Li Q et al. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high-dose cisplatin-induced nephrotoxicity. Oncol. Rep. 33(2), 751–757 (2015).
Medline CASGoogle Scholar
47. Wei J, Chen X, Li Q et al. ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity. Oncol. Rep. 31(4), 1599–1604 (2014).
Medline CASGoogle Scholar
48. Benoy IH, Salgado R, Van Dam P et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10(21), 7157–7162 (2004). • IL-8 promotes various types of cancers.
Medline CASGoogle Scholar
49. Singh JK, Farnie G, Bundred NJ et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and-independent mechanisms. Clin. Cancer Res. 19(3), 643–656 (2013).
Medline CASGoogle Scholar

Vol. 16, No. 14

Metrics

Downloaded 117 times

History

Received 14 January 2019

Accepted 26 March 2020

Published online 14 April 2020

Published in print May 2020

Information

Keywords

Author contributions

X Li, F Li and F Luo conceived the study. X Li, Y Zhang, W Walana and F Zhao conducted laboratory experiment and data analysis. X Li and W Walana drafted the manuscript. F Li and F Luo supervised the study. All authors read and approved the manuscript.

Acknowledgments

We thank all members of our laboratory for their helpful, suggestions and support. We also acknowledge the support from all the organizations involved in our study.

Financial & competing interests disclosure

This research work was supported by the National Natural Science Foundation of China (No. 81702626). The funding body had no involvement in the design of the study, collection, analysis and interpretation of data or writing of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Availability of data & materials

The data analyzed and presented in manuscript is available from the corresponding author upon reasonable request.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download